Last reviewed · How we verify

insulin infusion

IKFE Institute for Clinical Research and Development · FDA-approved active Small molecule

Insulin infusion delivers exogenous insulin directly into the bloodstream to regulate blood glucose by promoting cellular glucose uptake and storage.

Insulin infusion delivers exogenous insulin directly into the bloodstream to regulate blood glucose by promoting cellular glucose uptake and storage. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when oral agents are insufficient), Acute hyperglycemia in hospitalized patients.

At a glance

Generic nameinsulin infusion
Also known asinsuman rapid, Intravenous regular insulin infusion
SponsorIKFE Institute for Clinical Research and Development
Drug classInsulin (recombinant human insulin or insulin analog)
TargetInsulin receptor (INSR)
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Insulin infusion is a therapeutic delivery method for insulin, a hormone that binds to insulin receptors on cells to facilitate glucose uptake from the blood and promote glycogen synthesis and storage. This approach is used in acute care settings or for patients requiring continuous insulin delivery to maintain tight glycemic control. The infused insulin mimics the body's natural insulin secretion pattern to normalize blood glucose levels.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: